The SCALE Program: Liraglutide 3.0 mg for Chronic Weight Management

The context that made SCALE significant

When the SCALE program was designed and executed, the options for pharmacological weight management in the United States were limited. Orlistat (Xenical, alli) had been available since the late 1990s but with modest efficacy and tolerability challenges. Phentermine-topiramate (Qsymia) and naltrexone-bupropion (Contrave) received approval in 2012, followed by lorcaserin in 2012 (later withdrawn due to cancer signals). None of these produced mean weight losses consistently above 6 to 8%.

The Victoza dose used in T2DM (1.8 mg daily) had already shown meaningful weight effects in the SUSTAIN predecessor trials. Novo Nordisk hypothesized that a higher dose (3.0 mg) developed specifically for obesity might push that effect further. The SCALE program tested this hypothesis, positioning liraglutide 3.0 mg as the first GLP-1 receptor agonist aimed at obesity as a primary indication rather than as a consequence of treating diabetes.

Constituent trials

Approximate results from primary publications. AHI = apnea-hypopnea index; OSA = obstructive sleep apnea.

SCALE Obesity and Prediabetes: The pivotal trial

The largest SCALE trial (NCT01272219) enrolled 3,731 adults with a BMI of 30 or greater, or 27 or greater with dyslipidemia or hypertension. About two-thirds of participants had prediabetes at baseline. All participants received lifestyle counseling, and were randomized to liraglutide 3.0 mg or placebo for 56 weeks.^[1]

The mean weight reduction was 8.0% with liraglutide versus 2.6% with placebo. The proportion of participants achieving at least 5% weight loss was 63.2% with liraglutide versus 27.1% with placebo; those achieving at least 10% were 33.1% versus 10.6% respectively. Weight losses of 20% or more were rare at this dose and in this formulation.

An important pre-specified subgroup finding concerned the prediabetes participants: at the end of the trial, 69% of liraglutide recipients with prediabetes at baseline had normoglycemia, versus 33% of placebo recipients. This conversion back to normoglycemia was a compelling secondary finding for preventive medicine practitioners, and it was incorporated into later label discussions around diabetes prevention use cases.

Gastrointestinal side effects were the primary tolerability issue: nausea affected about 40% of liraglutide participants versus 14% of placebo, and vomiting occurred in about 15% versus 4%. Discontinuation due to adverse events was approximately 9.9% versus 4.3% for placebo.

SCALE Diabetes: Efficacy with coexisting T2DM

SCALE Diabetes (NCT01272232) enrolled 846 adults with type 2 diabetes and a BMI of 27 or greater, managed with diet alone or with metformin, a sulfonylurea, or both. The 56-week trial used the 3.0 mg and 1.8 mg doses, allowing within-program dose comparison, and found that both doses significantly outperformed placebo on weight and HbA1c.^[2]

The 3.0 mg dose produced approximately 6.0% weight reduction versus 2.0% for placebo, and HbA1c fell by approximately 1.3 percentage points from a baseline of about 7.9%. These results were meaningful but attenuated compared with the obesity-only population in the main pivotal trial, consistent with the general pattern of smaller pharmacological weight losses in T2DM populations.

SCALE Maintenance and SCALE Sleep Apnea

SCALE Maintenance (NCT01547182) employed a design that would later be replicated in the STEP and SURMOUNT programs: a low-calorie diet run-in followed by randomization. After approximately 4 to 12 weeks on a 1,200 to 1,400 kcal/day diet achieving at least 5% body-weight loss, participants were randomized to liraglutide 3.0 mg or placebo for 56 weeks. Those on liraglutide lost an additional 6.2% from the point of randomization while placebo participants regained 0.2%, a separation of approximately 6 percentage points.^[3]

SCALE Sleep Apnea (NCT01557166) was a 32-week trial in adults with moderate-to-severe obstructive sleep apnea and obesity (BMI 30 or greater) who were not on CPAP. The primary endpoint was change in apnea-hypopnea index. Liraglutide 3.0 mg reduced AHI by approximately 12.2 events per hour versus 6.1 with placebo, a statistically significant difference, accompanied by about 5.7% weight loss.^[4]This preceded and anticipated the later and more substantial OSA data from SURMOUNT-OSA, where tirzepatide produced AHI reductions of approximately 27 events per hour.

Regulatory outcome and subsequent market position

The FDA approved Saxenda (liraglutide 3.0 mg injection) for chronic weight management in December 2014, making it the first once-daily injectable GLP-1 receptor agonist approved specifically for obesity. The EMA followed with EU approval in 2015.

Saxenda occupied a dominant position in the injectable obesity market from 2015 until Wegovy (semaglutide 2.4 mg once weekly) was approved in 2021. The STEP-8 trial, which directly compared semaglutide 2.4 mg weekly against liraglutide 3.0 mg daily, showed that semaglutide produced approximately 15.8% weight loss compared with 6.4% for liraglutide, a difference of more than 9 percentage points. Following that publication and the subsequent approval and greater availability of Wegovy and then Zepbound, Saxenda prescriptions declined substantially in markets where the newer agents were accessible.

Saxenda retains a niche role in markets where semaglutide 2.4 mg or tirzepatide are not reimbursed, or for patients who have previously responded to liraglutide for diabetes management and prefer continuity of agent. It remains the benchmark against which the greater efficacy of newer anti-obesity agents is measured.

Historical significance of the SCALE program

The SCALE program's lasting contribution is not primarily the absolute weight numbers, which newer agents have surpassed, but the regulatory and clinical precedent it established. By generating a dedicated phase 3 obesity program distinct from the Victoza T2DM package, Novo Nordisk demonstrated that a GLP-1 receptor agonist could earn an obesity indication on its own terms rather than as a metabolic side effect of treating diabetes.

That precedent shaped the regulatory path for Wegovy and Zepbound, both of which followed the SCALE model of building dedicated obesity programs (STEP and SURMOUNT) separate from their parent T2DM programs (SUSTAIN and SURPASS).